Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 10;12(5):706-713.
doi: 10.4103/idoj.IDOJ_924_20. eCollection 2021 Sep-Oct.

Clinicopathological Profile of Childhood Onset Cutaneous Mastocytosis from a Tertiary Care Center in South India

Affiliations

Clinicopathological Profile of Childhood Onset Cutaneous Mastocytosis from a Tertiary Care Center in South India

Dharshini Sathishkumar et al. Indian Dermatol Online J. .

Abstract

Background: Mastocytosis is characterized by clonal proliferation of mast cells in various organs and can have isolated cutaneous or systemic involvement. Childhood-onset mastocytosis (COM) is usually cutaneous and regresses spontaneously, while adult-onset mastocytosis (AOM) is often persistent with systemic involvement. There is limited data on COM from India.

Objective: To elucidate the clinicopathological profile of COM.

Methods: We conducted a retrospective chart review of all the patients with histologically proven COM (≤16 years), presenting over 11 years (January 2009 to December 2019) to the Dermatology Department. We compiled the demographic data, clinical characteristics (morphology, extent, distribution), laboratory investigations, histopathology findings, imaging (ultrasound abdomen), c-KIT mutation results, where available, and other associated abnormalities, and grouped them according to the WHO classification for mastocytosis.

Results: Among the 66 patients with COM (M: F-1.6:1), 89.4% had onset before 2 years of age. The subtypes were: maculopapular cutaneous mastocytosis (MPCM: 44, 66.7%); mastocytoma of the skin (MOS: 19, 28.8%); diffuse cutaneous mastocytosis (DCM: 2, 3%) and indolent systemic mastocytosis (ISM: 1, 1.5%). Blistering was observed in 29 (43.9%) and Darier sign was elicited in 47 (71.2%) patients. Serum tryptase was elevated in 9/21 (42.9%) patients, but none had systemic mastocytosis. Three patients had c-KIT mutations (two in exon 8 and one in exon 17). Most patients were managed symptomatically and the patient with ISM improved with imatinib.

Conclusion: MPCM is the most common variant of COM and most patients had a disease onset before 2 years. Overall, COM had a good prognosis with rare systemic involvement, mitigating the need for extensive evaluation routinely in children.

Keywords: Childhood mastocytosis; c-KIT; cutaneous mastocytosis; mastocytoma; pediatric mastocytosis; tryptase; urticaria pigmentosa.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Patient flow chart.
Figure 2
Figure 2
(a) Multiple light brown to hyperpigmented macules in a patient with MPCM, (b) positive Darier sign in MPCM, (c) yellowish pseudoxanthomatous plaques on the neck of a patient with MPCM, (d) diffuse MPCM with multiple plaques, (e) MPCM with plaques showing blistering and ulceration, (f) solitary mastocytoma of the skin with positive Darier sign, (g) diffuse infiltration of the skin (h) with blistering in diffuse cutaneous mastocytosis.
Figure 3
Figure 3
Histopathology showing (a) dense diffuse infiltrates of mast cells in the upper third of the dermis (H and E, 50X), insert (H and E, 100X); (b) telangiectasia with mild perivascular infiltrates of lymphocytes and scattered mast cells in the superficial dermis, basal layer hyperpigmentation (H and E, 100X); (c) proliferated blood vessels with moderate aggregates of mast cells admixed with occasional lymphocytes and histiocytes (H and E, 100X); (d) intraepidermal bulla with diffuse and perivascular aggregates of mast cells in the dermis (H and E, 50X) (e) Mast cells highlighted using toluidine blue stain (200X); (f) CD117 positive mast cells (immunoperoxidase stain, 100X)
Figure 4
Figure 4
Sanger sequencing electropherogram of the c-KIT mutations identified in exon 17 and 8 in this study.

Similar articles

Cited by

  • Characteristics and Therapeutic Strategies for Diffuse Cutaneous Mastocytosis.
    Pernea P, Méni C, Rossignol J, Aubert H, Barbarot S, Bellon N, Bing-Lecointe AC, Bonigen J, Bursztejn AC, Carré D, Phan A, Puzenat E, Skowron F, Vabres P, Welfringer-Morin A, Drabent P, Fraitag S, Garcelon N, Agopian J, Dubreuil P, Mallet S, Barete S, Arock M, Hermine O, Bodemer C, Polivka L; CEREMAST network; and the. Pernea P, et al. JAMA Dermatol. 2025 Aug 1;161(8):855-862. doi: 10.1001/jamadermatol.2025.1488. JAMA Dermatol. 2025. PMID: 40434754

References

    1. Méni C, Bruneau J, Georgin-Lavialle S, Le Saché de Peufeilhoux L, Damaj G, Hadj-Rabia S, et al. Pediatric mastocytosis: A systematic review of 1747 cases. Br J Dermatol. 2015;172:642–51. - PubMed
    1. Hartmann K, Escribano L, Grattan C, Brockow K, Carter MC, Alvarez-Twose I, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma and Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016;137:35–45. - PubMed
    1. Bodemer C, Hermine O, Palmérini F, Yang Y, Grandpeix-Guyodo C, Leventhal PS, et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol. 2010;130:804–15. - PubMed
    1. Azaña JM, Torrelo A, Matito A. Update on mastocytosis (part 1): Pathophysiology, clinical features, and diagnosis. Actas Dermosifiliogr. 2016;107:5–14. - PubMed
    1. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, et al. Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future. Cancer Res. 2017;77:1261–70. - PMC - PubMed